Amicus Therapeutics, Inc. (NASDAQ:FOLD) surged 30.21% to a new 52-week high of $14.18 on Friday after announcing a nearly $5 billion merger with Biomarin Pharmaceutical, with shares reaching $14.36 at intra-day trading before closing at $14.18. The acquisition price is set at $14.50 per share, representing a 33% premium over Thursday’s closing price of $10.89. The deal awaits regulatory approvals, including shareholder approval. President and CEO Bradley Campbell expressed confidence in the merger, emphasizing the potential benefits for shareholders and rare disease patients.

Read more at Yahoo Finance: Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger